急性缺血性腦中風新療法 突破黃金治療3小時 2016-01-2614:39 〔記者林彥彤／台北報導〕救護車聲響，一名79歲的郭老先生昏迷且左邊肢體無力，經醫師診斷後發現右側內頸動脈及中大腦動脈嚴重阻塞，家屬決定接受「介入性動脈機械取栓法」，術後3個月恢復正常，目前僅有左手輕度活動不靈活，是長庚醫院執行介入性動脈機械取栓法的成功首例。 介入性動脈機械取栓法突破過去靜脈注射血栓溶解劑的侷限，針對中風發病超過3小時的病患透過導管技術，從微創口經動脈導引到阻塞的腦血管前端，再判斷是否應該取出血栓或是打通阻塞血管。長庚醫院腦血管科主任張健宏醫師說，腦部側枝循環的好壞是影響患者術後恢復的關鍵，而新技術治療則是延長治療急性中風的搶救黃金時間達12小時內。 醫師提醒，中風又被稱為沉默的重症。民眾應提早察覺中風症狀，如嘴歪眼斜、體無力、麻木、言語不清、構音障礙、大小便失禁和意識模糊甚至昏迷等。此外具有高血壓、心臟病、糖尿病和高膽固醇等慢性病患者平時要按時服藥，並注意冷熱溫差的改變。家屬若發現患者出現中風情形，一定要趕緊撥打119，若經評估後符合治療條件務必即時做出決定，才可避免肢體癱瘓等嚴重後遺症。 目前長庚醫院結合各科成立整合性急性腦中風治療小組，搶救中風患者的診斷及治療時間。介入性動脈機械取栓法的案例截至去年也已完成近50例，長庚醫院重症神經外科主治醫師王以舟說，今年2月1日健保也已將支架取栓費用納入，但患者是否適用手術還需待醫師團隊評估。
Wednesday, January 27, 2016
Athenex口服Docetaxel 進入IND (藥華Oraxol口服紫杉醇/ Oratecan口服喜樹鹼)
Athenex宣佈美國FDA批准Oradoxel的新藥臨床試驗申請 2016年01月26日 下午02:26紐約州 布法羅和香港2016年1月26日電 /美通社/ -- Athenex, Inc.今天宣佈，該公司已經獲得了美國食品藥品監督管理局（美國FDA）對繼續進行其自主研發的口服型多西他賽的臨床研究的批准。此次獲准繼續研究讓 Athenex 第六次向美國 FDA 成功提交了腫瘤新藥臨床試驗申請(IND)（這六次申請分別涉及五種口服抗癌藥和一種藥膏），這也預示著該公司的口服吸收平臺將推出第三種此類臨床候選藥物。多西他賽是一種成熟有效的高效能抗癌藥物。Athenex 已經為其開發了名為「Oradoxel」的口服型藥物。相應的 Athenex 腫瘤口服吸收技術以自主研發的 P-糖蛋白(Pgp)泵抑制劑（「Orascovery」平臺）為基礎，而這種泵抑制劑源自於Athenex 從商業合作夥伴 Hanmi Pharmaceuticals（韓美藥品）那裏獲得的獨家授權，2011年，Athenex獲得了相關技術在全球各主要地區的授權，但 Hanmi Pharmaceuticals 保留在韓國和日本地區進行開發的權利。Athenex 目前擁有處於晚期臨床研究階段的口服型紫杉醇和伊立替康，這些藥物在更早的臨床評估中展現出了頗有開發前途的特性。 Athenex 臨床開發和監管事務副總裁 Douglas Kramer 博士表示：「我們的團隊為 Oradoxel 向 FDA 提交了超過35,000頁的綜合 IND 資料，包括關於我們口服吸收平臺的信息。我們的 Pgp 泵抑制劑被證明能幫助提升知名腫瘤藥物的口服吸收水平，而如今這些藥物只能通過靜脈注射的方式向病人提供。我們現在很高興能夠創造無限的可能性，在幫助更多的癌症病人上面有一番作為。」 Athenex 臨床藥理學副總裁 Gerald Fetterly 博士補充說：「我們已經在臨床上瞭解到，將現有的靜脈注射高效能腫瘤藥物轉變成口服形式，可以為優化多種多樣的病人給藥方案開啟大門，而這些方案是不可能通過靜脈注射來實現的。以口服形式給藥能讓病人在更長的時間裏吸收活性強效藥物成分，臨床研究也表明在藥代動力學方面，口服型藥物在血液中的含量能達到預期，與靜脈注射形式相比，這樣臨床效果好，不良副作用也較少。」 Athenex 主席兼行政總裁 Johnson YN Lau（劉耀南）博士（擁有內外全科醫學士(MBBS)學位，並且是英國皇家內科醫師學會會員(FRCP)）則評論說：「我要祝賀我們的 Athenex 香港團隊和 Athenex 美國團隊，並且要感謝我們的合作者協助我們開展這個項目，達到了這一具有重要意義的成功監管里程碑。Oradoxel 項目最初由 Athenex 香港團隊在香港理工大學(The Hong Kong Polytechnic University)應用生物及化學科技學系(ABCT)的鄭家純藥物研發實驗室(Henry Cheng Research Laboratory)開發，這個項目還獲得了香港創新科技署(Hong Kong Innovation and Technology Commission)的 SERAP（小型企業研究資助計劃）等額撥款的部分支持。現在應該祝賀香港成為了面向全球癌症病人的重要藥物開發科學創新基地。我們所取得的這一成就還幫助加強了我們業務策略的成功實施，即在中國和美國之間搭建一座醫療科技的『橋樑』。」 除了公司業務所覆蓋的主要區域之外，Athenex 現在還和 Orascovery 平臺的發起者 Hanmi Pharmaceuticals，一起在韓國和日本開發 Oraxol 與 Oratecan，並和 PharmaEssentia（藥華醫藥股份有限公司）與 ZenRx 分別在臺灣和新加坡地區與新西蘭和澳洲地區進行開發。
Athenex, Inc.簡介 Athenex 創立於2003年，是一家全球專業腫瘤醫藥公司，主要關注新一代癌症疾病療法和支持療法的商業化開發。Athenex致力於提供能大大改善癌症病人的病情的創新藥物。我們的業務包含十種正在開發的自主研髮型創新藥物、醫療科技創新中心、產品開發團隊，以及跨越中國與北美的獨一無二的新興製造供應鏈。我們的雇員包括幾百名具有奉獻精神的專業人員，他們致力於達成改善全球癌症病人的生活的使命。憑藉我們主要集中於中美兩國並相互聯繫的創新、開發與製造事業，我們能在不同的大陸和多個監管環境中發現、開發和提供自主研發的醫療技術。我們已經在紐約州布法羅和克拉倫斯、新澤西州克蘭福德、香港、臺灣臺北及中國內地重慶市內的多個地點設立了辦事處。除了我們的辦事處之外，我們還在新西蘭但尼丁、香港、中國內地的廣州、韓國首爾、臺灣的臺北、危地馬拉的危地馬拉城與阿根廷布宜諾斯艾利斯擁有地區層面的開發合作夥伴。
Reference: 藥華 開發 Oraxol(口服紫杉醇)/ Oratecan(口服喜樹鹼) (licensed by Kinex)
Athenex Announces US FDA Allowance of the Investigation New Drug Application of Oradoxel, the Proprietary Oral Form of Docetaxel Buffalo, NY and Hong Kong- Athenex, Inc. announced today that it has received United States Food and Drug Administration (US FDA) allowance to proceed in the clinic with its proprietary oral form of Docetaxel. This allowance to proceed represents Athenex's sixth successful oncology investigational new drug (IND) application by the US FDA (5 oral anticancer drugs, one ointment) and the third such clinical drug candidate in Athenex's oral absorption platform. Docetaxel is an established and effective high potency anti-cancer drug. Athenex has developed an oral form, called Oradoxel. The Athenex oncology oral absorption technology is based on a proprietary P-glycoprotein (Pgp) pump inhibitor ("Orascovery" platform) licensed exclusively from our business partner, Hanmi Pharmaceuticals, in 2011 for all major worldwide territories except Korea and Japan that were retained by Hanmi Pharmaceuticals. Athenex currently has the oral forms of paclitaxel and irinotecan in later stage clinical studies, which showed promising profiles in earlier clinical evaluations. Douglas Kramer, MD, Athenex Vice President of Clinical Development and Regulatory Affairs stated "Our team submitted to the FDA a comprehensive IND package for Oradoxel of over 35,000 pages, including information on our oral absorption platform. Our Pgp pump inhibitor has been demonstrated to enhance the oral absorption of well-known oncology drugs that today are only available to patients as intravenous medicines. We are excited for the possibilities to make a difference in helping more cancer patients." Gerald Fetterly, PhD, Athenex Vice President of Clinical Pharmacology added "We have learned in the clinic that converting existing intravenous high potency oncology drugs into oral forms opens the door to optimizing a wide array of patient dosing regimens which cannot be achieved with IV. Oral forms of dosing allow the patients to be exposed over a longer period of time to the potent active pharmaceutical ingredients and clinical studies have shown expected pharmacokinetic blood levels of exposure; leading to good clinical efficacy with less adverse side effects compared with the intravenous counterparts." Athenex Chairman and CEO Johnson YN Lau, MBBS, MD, FRCP, commented, "I want to congratulate both our Athenex Hong Kong team and the Athenex US team, and thank our collaborators on this project on achieving this important successful regulatory milestone. The Oradoxel project was initially developed by the Athenex Hong Kong team in the Henry Cheng Research Laboratory for Drug Development, Department of Applied Biology and Chemical Technology (ABCT), The Hong Kong Polytechnic University and this project was also partially supported by a SERAP matching grant from the Hong Kong Innovation and Technology Commission. Hong Kong should be congratulated as an innovator of important drug development science for cancer patients globally. This accomplishment also reinforces the successful execution of our business strategy creating a medical technology bridge between China and the United States." In addition to its primary territories, Athenex is also developing Oraxol and Oratecan with Hanmi Pharmaceuticals, the originator of the Orascovery platform, in Korea and Japan, with PharmaEssentia in Taiwan and Singapore, and with ZenRx in New Zealand and Australia.
About Athenex, Inc. Founded in 2003, Athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. Our business includes 10 innovative proprietary products under development, medical technology innovation centers, product development teams and a unique emerging manufacturing supply chain across both China and North America. Our employees include several hundred dedicated professionals to the mission of improving the lives of cancer patients throughout the world. With our connected innovation, development and manufacturing presence concentrated in China and the US, we can identify, develop, and deliver proprietary medical technology across continents and multiple regulatory environments. We have offices in: Buffalo and Clarence New York, Cranford New Jersey, Hong Kong, Taipei Taiwan, and multiple locations in Chongqing, China. In addition to our offices, we have regional development partners in Dunedin New Zealand, Hong Kong, Guangzhou China, Seoul South Korea, Taipei Taiwan, Guatemala City, Guatemala, and Buenos Aires Argentina. Any opinions, findings, conclusions or recommendations expressed in this material/event do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Innovation and Technology Commission or the Small Entrepreneur Research Assistance Programme (SERAP) Project Assessment Panel.
Athenex Leadership Team
Athenex is led by an experienced global team in pharmaceutical drug development.
Johnson Y.N. Lau, MBBS, MD, FRCP Chief Executive Officer & Board Chairman, Johnson is a successful pharmaceutical executive who has had extensive leadership experience in both scientific and business management. As Chairman and CEO of Ribapharm, he launched the second largest biotech IPO in US history. During his tenure at Ribapharm, he met or exceeded Wall Street expectations each and every quarter. Prior to Ribapharm, he served as the Head of Worldwide Research and Development for ICN Pharmaceuticals. Prior, Johnson served as the Senior Director of Antiviral Therapy at Schering-Plough, where he played a key role in the FDA approval of Ribavirin/Interferon and Pegylated Interferon alpha-2b. Johnson has contributed more than 250 scientific publications in peer reviewed scientific journals, more than 50 editorials/reviews/chapters and has edited three books. He was a former Managing Director at Roth Capital Partners at its headquarters in Newport Beach, California and was also a Director of the Board of Chelsea Therapeutics (CHTP), serving as the Chair of the Audit and Finance Committee as well as the Corporate Governance Committee. He has served on the Board for a number of privately held companies. Johnson received his medical degree (MBBS) and medical doctorate degree (MD) from the University of Hong Kong. He is also a Fellow of the Royal College of Physicians. Johnson has served as the Chairman of the Board of Athenex since its inception and assumed the role of CEO in mid 2011.
Flint D. Besecker, CPA Chief Operating Officer & Board Director, Flint is a veteran in the healthcare industry with a proven track record building large-scale growth oriented platforms focused in the US. Flint has held a number of nationwide executive positions in the healthcare and financial industry, including founding Care Investment Trust (CRE-NYSE), a healthcare focused Real Estate Investment Trust and founding CIT Healthcare (CIT-NYSE) where he served as its President. Flint has served on numerous Boards including Board Chair of Care Investment Trust and subsequently its lead Independent Director after its sale. He has also served as Board Director and Chair of Compensation Committee of Allion Healthcare (ALLI- NASDAQ) and has served on numerous private boards. Prior to 2004, Flint held a variety of national executive leadership positions in the healthcare industry including GE Healthcare Financial Services (GE-NYSE), Heller Healthcare Finance (HF-NYSE) and Healthcare Financial Partners (HCF-NYSE). He received a BS in Accounting from Canisius College in 1988 and is a Certified Public Accountant. Flint resides in Western New York.
Rudolf Kwan, MBBS, MRCP Chief Medical Officer, Rudolf has had a successful career in the pharmaceutical industry with over twenty years of experience in global clinical development and operations. Before joining Athenex, he served dual roles at Schering-Plough (SP) as Vice President and Regional Head of Asia Pacific Global Clinical Operations and Vice President of Global Clinical Development, CNS. In the clinical operations position, Rudolf successfully recruited Heads of Clinical Operations for China, South East Asia, Australia, Taiwan and South Korea and set up the infrastructure to conduct global clinical trials in Asia Pacific for Schering-Plough. As Vice President of Global Clinical Development, CNS, he was responsible for the clinical development of all SP central nervous system drugs, globally. Major achievements included developing and executing a bioequivalence registration strategy for a new formulation of Temodol, for glioblastoma, which led to a simultaneous global registration. He also designed and executed multiple global development programs. Earlier at Schering-Plough, Rudolf held various clinical operation positions with increasing responsibility. He held similar positions at Chiron Corporation and at Smith Kline Beecham. Rudolf obtained his medical degree in Hong Kong and did subsequent training in England. He is a member and Chair of the Data Monitoring and Safety Board and Protocol Review Board for the Clinical Trial Network of the National Institute on Drug Abuse of the National Institute of Health in the USA (NIH). He is also a member of several advisory panels and grant review panels for NIH.
David Hangauer, PhD Chief Scientific Officer, David is a leader in the field of structure based drug design. Following doctoral studies in chemistry at the University at Buffalo, he spent ten years at Merck Sharp and Dohme Research Laboratories, where he directed a variety of drug discovery projects. In 1989, he returned to academia and joined the chemistry faculty at SUNY at Buffalo, where he has had a productive career that has focused on developing protein kinase inhibitors. David's expertise has been sought by pharmaceutical and biotechnology companies worldwide, including: Lederle/Wyeth-Ayerst Research Laboratories; New Medical Technologies; Sphinx/Eli Lilly Pharmaceuticals Inc.; Yuhan Corporation; Periodontix, Inc.; ICAgen, Inc.; ARPIDA, Scientific Advisory Board & Founding Scientist; and Signal Pharmaceuticals, Inc. Most notably, he led the chemistry effort at Hypnion, Inc., which was sold to Eli Lilly in 2009 for more than $300 million. The company's major asset was an insomnia drug that was designed and discovered under the leadership of David.
Wing-Kai Chan, MD, MBBS, FRACP Head of Asia / Pacific Clinical , Wing-Kai's roles have included Director, National Center of Excellence for Clinical Trial and Research at the National University Hospital, Taiwan, and Medical Director in Roche Asia/Pacific and in that capacity, participated in the clinical development of a number of anti-cancer drugs such as: Rituxan, Herceptin and Xeloda, to name a few. Wing-Kai is a medical graduate of the University of New South Wales, Sydney, Australia and a Fellow of the Royal Australian College of Physicians. He is also a member of American Society of Clinical Oncology. Wing-Kai has authored many publications in clinical oncology over the course of his distinguished career. Wing-Kai is based in Taipei, Taiwan and Hong Kong.
William ZuoWilliam Zuo, PhD President of Polymed Therapeutics, William has over 21 years of experience in pharmaceutical business, and specializes in the manufacturing, sale and marketing of various complex "Active Pharmaceutical Ingredients." William received his PhD in Nanotechnology from Rice University.
Teresa Bair, ESQ Senior VP of Corporate Development & Legal Affairs Teresa is a seasoned commercial attorney who has extensive experience handling complex business matters in both the board room and court room. Prior to joining Athenex, she served as a partner at Harris Beach PLLC, a nationally recognized law firm. Teresa successfully represented business clients, including Fortune 500 companies, in matters involving mergers and acquisitions, intellectual property, international law, equity investments, corporate governance, and contract transactions. Teresa has been consistently recognized by peer journals as a "Super Lawyer" in Business Litigation and Intellectual Property. Teresa received her law degree (JD) from University at Buffalo School of Law, and a Bachelor of Science in Business Administration from Bowling Green State University.
Stephen Yeung, CA Chief Business Officer – Asia Pacific, Stephen is a seasoned financial professional with a proven track record of over 35 years of leadership experience in accounting, treasury, corporate finance, business and project development and management in direct and private equity investments, private family wealth and fund management. After launching his career in Canada with the largest multinational oil conglomerate in the country, Stephen relocated to the company's Asia Pacific regional head office in Hong Kong. Capitalizing on the significant economic growth in Greater China in the 1980's, Stephen moved into investment banking/corporate finance; direct, private equity, and private family fund investment development and management; all with large local corporations and local listed companies in Hong Kong, including a fortune 500 group. He holds a Bachelor of Arts in Mathematics and Accounting from St. John's University, Minn., USA, and a Master of Business Administration in Finance from The University of Toronto, Ont., Canada. He is also a Chartered Accountant registered with the Province of Ontario in Canada.
Benjamin Lee, PharmD, Hong Kong Research & Product Development Leader, Benjamin is the President of Comprehensive Drug Enterprises Ltd, an award winning, technology-driven company that provides innovative solutions for drug delivery system. Founded in 2005 and located in HK Science Park, it has products from the pre-clinical to the clinical stage of development. Benjamin was also an adjunct member of the Faculty of Medicine at the Chinese University in Hong Kong School of Pharmacy. He holds a Doctorate from the University of Kentucky College of Pharmacy. He trained under Drug Development and Clinical Research Fellowships at Glaxo Wellcome and the University of North Carolina, School of Pharmacy. Upon completion of his Fellowships, Benjamin joined Glaxo Wellcome as a Senior Research Scientist, rising to Lead Scientist and group manager in Clinical Development Center at GlaxoSmithKline. He has participated in the development of several of the GlaxoSmithKline respiratory drugs development, regulatory approval and marketing; and has also participated in product development and registration in neurology and pain management.
Tracey Burr, PhD, Chief Scientific Officer, Active Pharmaceutical Ingredients, Tracey has been engaged in leading product development, portfolio management and lifecycle management for nearly 20 years, including over 10 as a successful executive in the international pharmaceutical industry. Tracey is the CSO of our API manufacturing platform, with significant pharmaceutical product and regulatory experience in worldwide markets. She has been instrumental in successfully filing numerous ANDA/NDAs/Dossiers and has actively contributed to the development of over 20 products through the drug development process, from target identification, R&D, regulatory approval, product launch and post-commercialization support. Under her leadership, pharmaceutical companies have seen dramatic increases in R&D scope, regulatory approvals, sales, and global production. She now brings her characteristic combination of discipline, vigor and vision to the development and commercialization of Athenex products. Prior to joining Athenex as CSO, Tracey worked for 15 years as a CSO for pharmaceutical companies in the USA, China, Switzerland and Germany. Tracey received an MSc in Organic Chemistry from the California Institute of Technology (Caltech), and a PhD at the Massachusetts Institute of Technology (MIT) in Materials Science and Engineering.
Stephen A. Panaro, PhD QuaDPharma, President, Stephen has over 12 years of experience in the pharmaceutical industry. His experience spans from drug discovery and API synthesis, to large-scale commercial production of finished products across many different dosage forms and packaging configurations. Throughout his carrier, Stephen has overseen personnel in nanotechnology, quality control (QC) chemistry, QC microbiology, customer service, project management and production, to name a few. Most recently, Stephen founded QuaDPharma based on his experience with clinical and commercial manufacturing. He wanted to create a company unlike the large-scale contract manufacturing organizations of today and focus on projects, and products, that require small to mid-scale manufacturing. The clients that sponsor these products require a unique blend of customer service and technical expertise. QuaDPharma provides just the right environment for development and commercialization of these innovative pharmaceutical products.
Board of Directors The Athenex Board of Directors is composed of carefully selected professionals who bring a wealth of governance and global corporate experience.
Johnson Y.N. Lau, MBBS, MD, FRCP Chief Executive Officer & Board Chairman Johnson is a successful pharmaceutical executive who has had extensive leadership experience in both scientific and business management. As Chairman and CEO of Ribapharm, he launched the second largest biotech IPO in US history. During his tenure at Ribapharm, he met or exceeded Wall Street expectations each and every quarter. Prior to Ribapharm, he served as the Head of Worldwide Research and Development for ICN Pharmaceuticals. Prior, Johnson served as the Senior Director of Antiviral Therapy at Schering-Plough, where he played a key role in the FDA approval of Ribavirin/Interferon and Pegylated Interferon alpha-2b. Johnson has contributed more than 250 scientific publications in peer reviewed scientific journals, more than 50 editorials/reviews/chapters and has edited three books. He was a former Managing Director at Roth Capital Partners at its headquarters in Newport Beach, California and was also a Director of the Board of Chelsea Therapeutics (CHTP), serving as the Chair of the Audit and Finance Committee as well as the Corporate Governance Committee. He has served on the Board for a number of privately held companies. Johnson received his medical degree (MBBS) and medical doctorate degree (MD) from the University of Hong Kong. He is also a Fellow of the Royal College of Physicians. Johnson has served as the Chairman of the Board of Athenex since its inception and assumed the role of CEO in mid 2011.
Jinn Wu, PhD Chief Executive Officer, Xenobiotic Laboratories Jinn is the Founder and President of Xenobiotics Laboratory (XBL) in Princeton, New Jersey, a contract research organization that provides an extensive array of clinical and preclinical research services to the biotechnology and pharmaceutical industry. Jinn earned a PhD in Natural Products and Medicinal Chemistry from Ohio State University and spent several years as a research scientist at FMC Corporation before starting XBL. He is an adjunct professor at the University of Medicine and Dentistry of New Jersey and is a member of the American Association of Pharmaceutical Scientists (AAPS), the International Society for the Study of Xenobiotics (ISSX), the American Society of Pharmacognosy (ASP) and the American Chemical Society (ACS). He serves on the Board of Directors of Enhance Biotech Inc. and has served on the Board of Ardent Pharmaceuticals.
Flint D. Besecker, CPA Chief Operating Officer & Board Director Flint is a veteran in the healthcare industry with a proven track record building large-scale growth oriented platforms focused in the US. Flint has held a number of nationwide executive positions in the healthcare and financial industry, including founding Care Investment Trust (CRE-NYSE), a healthcare focused Real Estate Investment Trust and founding CIT Healthcare (CIT-NYSE) where he served as its President. Flint has served on numerous Boards including Board Chair of Care Investment Trust and subsequently its lead Independent Director after its sale. He has also served as Board Director and Chair of Compensation Committee of Allion Healthcare (ALLI- NASDAQ) and has served on numerous private boards. Prior to 2004, Flint held a variety of national executive leadership positions in the healthcare industry including GE Healthcare Financial Services (GE-NYSE), Heller Healthcare Finance (HF-NYSE) and Healthcare Financial Partners (HCF-NYSE). He received a BS in Accounting from Canisius College in 1988 and is a Certified Public Accountant. Flint resides in Western New York.
kim-cKim Campbell, PC, CC, OBC, QC Canada's 19th Prime Minister The Right Honourable Kim Campbell served as Canada's nineteenth and first female Prime Minister in 1993. She previously held cabinet portfolios as Minister of Justice and Attorney General, Minister of State for Indian Affairs and Northern Development and Minister of National Defence and Minister of Veterans' Affairs. She was the first woman to hold the Justice and Defence portfolios, and the first woman to be Defence Minister of a NATO country. Kim participated in major international meetings including the Commonwealth, NATO, the G-7 Summit and the United Nations General Assembly. After her tenure as Prime Minister, Kim was a fellow at the Institute of Politics (Spring 1994) and the Joan Shorenstein Center for the Study of Press and Politics (1994-1995) at the Harvard Kennedy School of Government. She served as the Canadian Consul General in Los Angeles (1996-2000), then returned to Harvard to teach at the Center for Public Leadership at the Kennedy School (2001- 2004). Kim is a founding member of the Club of Madrid, an organization of former heads of government and state who work to promote democratic values. She served as Secretary General (2004- 2006). She also has served as its Acting President in 2002, its Vice President in 2003-2004 and served on its Board of Directors from 2007-2011. Kim is a member and chair emerita of the Council of Women World Leaders (1999-2003). The Council's membership consists of women who hold or have held the office of President or Prime Minister. Kim is a member of the International Women's Forum, a global organization of women of significant and diverse achievement. She served as its president (2003-2005) and was inducted into the IWF Hall of Fame in 2008. Today, Kim devotes the majority of her time to serving as the founding principal of the new Peter Lougheed Leadership College at the University of Alberta. She also chairs the steering committee for the World Movement for Democracy, and is a trustee of the International Center for the Study of Radicalisation and Political Violence (ICSR) at King's College London. She is a member of the Pacific Council on International Policy, (the West Coast affiliate of the Council on Foreign Relations) and the Global Council of the Asia Society of New York. She is on the advisory board of Equal Voice and an honorary patron of Informed Opinions. She is also a senior advisor to the Crisis Group and an honorary board member of the Climate Action Reserve and previously served as a trustee of the Salk Institute for Biological Studies 2007-2010.
Song-Yi_Zhang-500x500Song-Yi Zhang, JD Founder and Chairman, Mandra Capital Ltd. Song-Yi is the founder of Mandra Capital, an investment holding company focused on early stage opportunities in internet, biomedicine, materials and technologies. Song-Yi has more than twenty years of investment banking and direct investment experience. In addition to his responsibilities at Mandra Capital, Song-Yi serves as a director of SINA Corporation, a company listed on the Nasdaq Stock Market, and an independent non-executive director of China Long Yuan Electric Power Group Corp., a company listed on Hong Kong Stock Exchange. Prior to founding Mandra Capital, Song-Yi served as a managing director of Asia Merger, Acquisition and Divestiture Group, and the co-head of Asia Resources and Infrastructure Group of Morgan Stanley, and a senior associate of Milbank, Tweed, Hadley & McCloy LLP. Song-Yi holds a Juris Doctor degree from Yale University.
Specialist in General Surgery, Pedder Clinic Manson is a very successful doctor, entrepreneur and philanthropist. Manson is the Founder of the Pedder Clinic, which is one of the largest private medical practices in Hong Kong. Manson is also the Dean of the Faculty of Health Sciences at the University of Macau (MUST), President of the Macau Healthcare Management and Promotion Association (MHMPA), Vice-Chairman of Chinese Endoscopic Doctors Association, and Vice Director of Specialist Committee for Quality Evaluation of Clinical Endoscopy Diagnosis and Treatment, Department of Medical Service Supervision, Ministry of Health of People's Republic of China, among many other leadership positions. Manson received the 2009 "ENDOS Medical Science and Technology Award – International Outstanding Leadership Award in Endoscopy" during the First World Conference and World Endoscopy Expo. Having received his medical degree (MBBS) from the University of Hong Kong in 1982, Manson was appointed faculty in the Surgical Unit of the University of Hong Kong. Manson has published many original research papers in high-ranking international medical journals and as chapters in various academic books which is focusing on minimally invasive treatment for esophageal surgery. Manson is actively assisting Athenex to develop an Asian Business Strategy. Manson, has been awarded the 2014 Gusi Peace Prize in Humanitarianism for his remarkable contributions to medical education, healthcare delivery and cross-border biotechnology developments that act as a bridge both within Asia and across continents
Board of Directors The Athenex Board of Directors is composed of carefully selected professionals who bring a wealth of governance and global corporate experience.
Johnson Y.N. Lau, MBBS, MD, FRCP Chief Executive Officer & Board Chairman Johnson is a successful pharmaceutical executive who has had extensive leadership experience in both scientific and business management. As Chairman and CEO of Ribapharm, he launched the second largest biotech IPO in US history. During his tenure at Ribapharm, he met or exceeded Wall Street expectations each and every quarter. Prior to Ribapharm, he served as the Head of Worldwide Research and Development for ICN Pharmaceuticals. Prior, Johnson served as the Senior Director of Antiviral Therapy at Schering-Plough, where he played a key role in the FDA approval of Ribavirin/Interferon and Pegylated Interferon alpha-2b. Johnson has contributed more than 250 scientific publications in peer reviewed scientific journals, more than 50 editorials/reviews/chapters and has edited three books. He was a former Managing Director at Roth Capital Partners at its headquarters in Newport Beach, California and was also a Director of the Board of Chelsea Therapeutics (CHTP), serving as the Chair of the Audit and Finance Committee as well as the Corporate Governance Committee. He has served on the Board for a number of privately held companies. Johnson received his medical degree (MBBS) and medical doctorate degree (MD) from the University of Hong Kong. He is also a Fellow of the Royal College of Physicians. Johnson has served as the Chairman of the Board of Athenex since its inception and assumed the role of CEO in mid 2011.
Jinn Wu, PhD Chief Executive Officer, Xenobiotic Laboratories Jinn is the Founder and President of Xenobiotics Laboratory (XBL) in Princeton, New Jersey, a contract research organization that provides an extensive array of clinical and preclinical research services to the biotechnology and pharmaceutical industry. Jinn earned a PhD in Natural Products and Medicinal Chemistry from Ohio State University and spent several years as a research scientist at FMC Corporation before starting XBL. He is an adjunct professor at the University of Medicine and Dentistry of New Jersey and is a member of the American Association of Pharmaceutical Scientists (AAPS), the International Society for the Study of Xenobiotics (ISSX), the American Society of Pharmacognosy (ASP) and the American Chemical Society (ACS). He serves on the Board of Directors of Enhance Biotech Inc. and has served on the Board of Ardent Pharmaceuticals.
Flint D. Besecker, CPA Chief Operating Officer & Board Director Flint is a veteran in the healthcare industry with a proven track record building large-scale growth oriented platforms focused in the US. Flint has held a number of nationwide executive positions in the healthcare and financial industry, including founding Care Investment Trust (CRE-NYSE), a healthcare focused Real Estate Investment Trust and founding CIT Healthcare (CIT-NYSE) where he served as its President. Flint has served on numerous Boards including Board Chair of Care Investment Trust and subsequently its lead Independent Director after its sale. He has also served as Board Director and Chair of Compensation Committee of Allion Healthcare (ALLI- NASDAQ) and has served on numerous private boards. Prior to 2004, Flint held a variety of national executive leadership positions in the healthcare industry including GE Healthcare Financial Services (GE-NYSE), Heller Healthcare Finance (HF-NYSE) and Healthcare Financial Partners (HCF-NYSE). He received a BS in Accounting from Canisius College in 1988 and is a Certified Public Accountant. Flint resides in Western New York.
kim-cKim Campbell, PC, CC, OBC, QC Canada's 19th Prime Minister The Right Honourable Kim Campbell served as Canada's nineteenth and first female Prime Minister in 1993. She previously held cabinet portfolios as Minister of Justice and Attorney General, Minister of State for Indian Affairs and Northern Development and Minister of National Defence and Minister of Veterans' Affairs. She was the first woman to hold the Justice and Defence portfolios, and the first woman to be Defence Minister of a NATO country. Kim participated in major international meetings including the Commonwealth, NATO, the G-7 Summit and the United Nations General Assembly. After her tenure as Prime Minister, Kim was a fellow at the Institute of Politics (Spring 1994) and the Joan Shorenstein Center for the Study of Press and Politics (1994-1995) at the Harvard Kennedy School of Government. She served as the Canadian Consul General in Los Angeles (1996-2000), then returned to Harvard to teach at the Center for Public Leadership at the Kennedy School (2001- 2004). Kim is a founding member of the Club of Madrid, an organization of former heads of government and state who work to promote democratic values. She served as Secretary General (2004- 2006). She also has served as its Acting President in 2002, its Vice President in 2003-2004 and served on its Board of Directors from 2007-2011. Kim is a member and chair emerita of the Council of Women World Leaders (1999-2003). The Council's membership consists of women who hold or have held the office of President or Prime Minister. Kim is a member of the International Women's Forum, a global organization of women of significant and diverse achievement. She served as its president (2003-2005) and was inducted into the IWF Hall of Fame in 2008. Today, Kim devotes the majority of her time to serving as the founding principal of the new Peter Lougheed Leadership College at the University of Alberta. She also chairs the steering committee for the World Movement for Democracy, and is a trustee of the International Center for the Study of Radicalisation and Political Violence (ICSR) at King's College London. She is a member of the Pacific Council on International Policy, (the West Coast affiliate of the Council on Foreign Relations) and the Global Council of the Asia Society of New York. She is on the advisory board of Equal Voice and an honorary patron of Informed Opinions. She is also a senior advisor to the Crisis Group and an honorary board member of the Climate Action Reserve and previously served as a trustee of the Salk Institute for Biological Studies 2007-2010.
Song-Yi_Zhang-500x500Song-Yi Zhang, JD Founder and Chairman, Mandra Capital Ltd. Song-Yi is the founder of Mandra Capital, an investment holding company focused on early stage opportunities in internet, biomedicine, materials and technologies. Song-Yi has more than twenty years of investment banking and direct investment experience. In addition to his responsibilities at Mandra Capital, Song-Yi serves as a director of SINA Corporation, a company listed on the Nasdaq Stock Market, and an independent non-executive director of China Long Yuan Electric Power Group Corp., a company listed on Hong Kong Stock Exchange. Prior to founding Mandra Capital, Song-Yi served as a managing director of Asia Merger, Acquisition and Divestiture Group, and the co-head of Asia Resources and Infrastructure Group of Morgan Stanley, and a senior associate of Milbank, Tweed, Hadley & McCloy LLP. Song-Yi holds a Juris Doctor degree from Yale University.
Specialist in General Surgery, Pedder Clinic Manson is a very successful doctor, entrepreneur and philanthropist. Manson is the Founder of the Pedder Clinic, which is one of the largest private medical practices in Hong Kong. Manson is also the Dean of the Faculty of Health Sciences at the University of Macau (MUST), President of the Macau Healthcare Management and Promotion Association (MHMPA), Vice-Chairman of Chinese Endoscopic Doctors Association, and Vice Director of Specialist Committee for Quality Evaluation of Clinical Endoscopy Diagnosis and Treatment, Department of Medical Service Supervision, Ministry of Health of People's Republic of China, among many other leadership positions. Manson received the 2009 "ENDOS Medical Science and Technology Award – International Outstanding Leadership Award in Endoscopy" during the First World Conference and World Endoscopy Expo. Having received his medical degree (MBBS) from the University of Hong Kong in 1982, Manson was appointed faculty in the Surgical Unit of the University of Hong Kong. Manson has published many original research papers in high-ranking international medical journals and as chapters in various academic books which is focusing on minimally invasive treatment for esophageal surgery. Manson is actively assisting Athenex to develop an Asian Business Strategy. Manson, has been awarded the 2014 Gusi Peace Prize in Humanitarianism for his remarkable contributions to medical education, healthcare delivery and cross-border biotechnology developments that act as a bridge both within Asia and across continents
Athenex Board of Directors
Johnson Y.N. Lau, MBBS, MD, FRCP Chief Executive Officer & Board Chairman Johnson is a successful pharmaceutical executive who has had extensive leadership experience in both scientific and business management. As Chairman and CEO of Ribapharm, he launched the second largest biotech IPO in US history. During his tenure at Ribapharm, he met or exceeded Wall Street expectations each and every quarter. Prior to Ribapharm, he served as the Head of Worldwide Research and Development for ICN Pharmaceuticals. Prior, Johnson served as the Senior Director of Antiviral Therapy at Schering-Plough, where he played a key role in the FDA approval of Ribavirin/Interferon and Pegylated Interferon alpha-2b. Johnson has contributed more than 250 scientific publications in peer reviewed scientific journals, more than 50 editorials/reviews/chapters and has edited three books. He was a former Managing Director at Roth Capital Partners at its headquarters in Newport Beach, California and was also a Director of the Board of Chelsea Therapeutics (CHTP), serving as the Chair of the Audit and Finance Committee as well as the Corporate Governance Committee. He has served on the Board for a number of privately held companies. Johnson received his medical degree (MBBS) and medical doctorate degree (MD) from the University of Hong Kong. He is also a Fellow of the Royal College of Physicians. Johnson has served as the Chairman of the Board of Athenex since its inception and assumed the role of CEO in mid 2011.
Jinn Wu, PhD Chief Executive Officer, Xenobiotic Laboratories Jinn is the Founder and President of Xenobiotics Laboratory (XBL) in Princeton, New Jersey, a contract research organization that provides an extensive array of clinical and preclinical research services to the biotechnology and pharmaceutical industry. Jinn earned a PhD in Natural Products and Medicinal Chemistry from Ohio State University and spent several years as a research scientist at FMC Corporation before starting XBL. He is an adjunct professor at the University of Medicine and Dentistry of New Jersey and is a member of the American Association of Pharmaceutical Scientists (AAPS), the International Society for the Study of Xenobiotics (ISSX), the American Society of Pharmacognosy (ASP) and the American Chemical Society (ACS). He serves on the Board of Directors of Enhance Biotech Inc. and has served on the Board of Ardent Pharmaceuticals.
Flint D. Besecker, CPA Chief Operating Officer & Board Director Flint is a veteran in the healthcare industry with a proven track record building large-scale growth oriented platforms focused in the US. Flint has held a number of nationwide executive positions in the healthcare and financial industry, including founding Care Investment Trust (CRE-NYSE), a healthcare focused Real Estate Investment Trust and founding CIT Healthcare (CIT-NYSE) where he served as its President. Flint has served on numerous Boards including Board Chair of Care Investment Trust and subsequently its lead Independent Director after its sale. He has also served as Board Director and Chair of Compensation Committee of Allion Healthcare (ALLI- NASDAQ) and has served on numerous private boards. Prior to 2004, Flint held a variety of national executive leadership positions in the healthcare industry including GE Healthcare Financial Services (GE-NYSE), Heller Healthcare Finance (HF-NYSE) and Healthcare Financial Partners (HCF-NYSE). He received a BS in Accounting from Canisius College in 1988 and is a Certified Public Accountant. Flint resides in Western New York.
kim-cKim Campbell, PC, CC, OBC, QC Canada's 19th Prime Minister The Right Honourable Kim Campbell served as Canada's nineteenth and first female Prime Minister in 1993. She previously held cabinet portfolios as Minister of Justice and Attorney General, Minister of State for Indian Affairs and Northern Development and Minister of National Defence and Minister of Veterans' Affairs. She was the first woman to hold the Justice and Defence portfolios, and the first woman to be Defence Minister of a NATO country. Kim participated in major international meetings including the Commonwealth, NATO, the G-7 Summit and the United Nations General Assembly. After her tenure as Prime Minister, Kim was a fellow at the Institute of Politics (Spring 1994) and the Joan Shorenstein Center for the Study of Press and Politics (1994-1995) at the Harvard Kennedy School of Government. She served as the Canadian Consul General in Los Angeles (1996-2000), then returned to Harvard to teach at the Center for Public Leadership at the Kennedy School (2001- 2004). Kim is a founding member of the Club of Madrid, an organization of former heads of government and state who work to promote democratic values. She served as Secretary General (2004- 2006). She also has served as its Acting President in 2002, its Vice President in 2003-2004 and served on its Board of Directors from 2007-2011. Kim is a member and chair emerita of the Council of Women World Leaders (1999-2003). The Council's membership consists of women who hold or have held the office of President or Prime Minister. Kim is a member of the International Women's Forum, a global organization of women of significant and diverse achievement. She served as its president (2003-2005) and was inducted into the IWF Hall of Fame in 2008. Today, Kim devotes the majority of her time to serving as the founding principal of the new Peter Lougheed Leadership College at the University of Alberta. She also chairs the steering committee for the World Movement for Democracy, and is a trustee of the International Center for the Study of Radicalisation and Political Violence (ICSR) at King's College London. She is a member of the Pacific Council on International Policy, (the West Coast affiliate of the Council on Foreign Relations) and the Global Council of the Asia Society of New York. She is on the advisory board of Equal Voice and an honorary patron of Informed Opinions. She is also a senior advisor to the Crisis Group and an honorary board member of the Climate Action Reserve and previously served as a trustee of the Salk Institute for Biological Studies 2007-2010.
Song-Yi_Zhang-500x500Song-Yi Zhang, JD Founder and Chairman, Mandra Capital Ltd. Song-Yi is the founder of Mandra Capital, an investment holding company focused on early stage opportunities in internet, biomedicine, materials and technologies. Song-Yi has more than twenty years of investment banking and direct investment experience. In addition to his responsibilities at Mandra Capital, Song-Yi serves as a director of SINA Corporation, a company listed on the Nasdaq Stock Market, and an independent non-executive director of China Long Yuan Electric Power Group Corp., a company listed on Hong Kong Stock Exchange. Prior to founding Mandra Capital, Song-Yi served as a managing director of Asia Merger, Acquisition and Divestiture Group, and the co-head of Asia Resources and Infrastructure Group of Morgan Stanley, and a senior associate of Milbank, Tweed, Hadley & McCloy LLP. Song-Yi holds a Juris Doctor degree from Yale University.
Specialist in General Surgery, Pedder Clinic Manson is a very successful doctor, entrepreneur and philanthropist. Manson is the Founder of the Pedder Clinic, which is one of the largest private medical practices in Hong Kong. Manson is also the Dean of the Faculty of Health Sciences at the University of Macau (MUST), President of the Macau Healthcare Management and Promotion Association (MHMPA), Vice-Chairman of Chinese Endoscopic Doctors Association, and Vice Director of Specialist Committee for Quality Evaluation of Clinical Endoscopy Diagnosis and Treatment, Department of Medical Service Supervision, Ministry of Health of People's Republic of China, among many other leadership positions. Manson received the 2009 "ENDOS Medical Science and Technology Award – International Outstanding Leadership Award in Endoscopy" during the First World Conference and World Endoscopy Expo. Having received his medical degree (MBBS) from the University of Hong Kong in 1982, Manson was appointed faculty in the Surgical Unit of the University of Hong Kong. Manson has published many original research papers in high-ranking international medical journals and as chapters in various academic books which is focusing on minimally invasive treatment for esophageal surgery. Manson is actively assisting Athenex to develop an Asian Business Strategy. Manson, has been awarded the 2014 Gusi Peace Prize in Humanitarianism for his remarkable contributions to medical education, healthcare delivery and cross-border biotechnology developments that act as a bridge both within Asia and across continents
生展 陳威仁 解除競業禁止
生展生技：本公司董事會決議通過解除經理人競業禁止 鉅亨網新聞中心 2016-01-26 18:16:10 第三十四條 第22款1.董事會決議日期:105/01/26 2.許可從事競業行為之經理人姓名及職稱:陳威仁/總經理3.許可從事競業行為之項目:在無損及本公司利益解除經理人競業禁止限制。4.許可從事競業行為之期間:任職本公司經理人期間。5.決議情形（請依公司法第32條說明表決結果）:出席董事均無異議通過。6.所許可之競業行為如屬大陸地區事業之營業者，經理人姓名及職稱（非屬大陸地區事業之營業者，以下欄位請輸不適用）:不適用。7.所擔任該大陸地區事業之公司名稱及職務:不適用。8.所擔任該大陸地區事業地址:不適用。9.所擔任該大陸地區事業營業項目:不適用。10.對本公司財務業務之影響程度:不適用。11.經理人如有對該大陸地區事業從事投資者，其投資金額及持股比例:不適用。12.其他應敘明事項:無。
奇美全人醫療 建置 急診安寧團隊
臨終照護最後一哩路 奇美醫率先有急診安寧團隊 NOWnews 2016/01/26 記者黃芳祿／台南報導奇美醫學中心急診安寧團隊由急診醫護人員受訓後成立，減少照會的繁瑣程序及等待，更直接地在第一時間給予病人適當的安寧療護。提升急診醫護人員對安寧的認識及理念，帶動台灣急診安寧療護。奇美醫學中心全人醫療科主治醫師翁子傑表示，當疾病進展至末期，病人遭遇身體上的不適，常常送至急診尋求醫療上的協助，緩解症狀以及心中的焦躁不安，但是，安寧療護在急診的推動是充滿阻力的。急診醫師很忙，沒有時間好好坐下來了解病人及家屬的需求。急診醫師在短時間內無法和病人及家屬建立良好的醫病關係，也無法在短時間內與病人談論到生死的議題。安寧療護不適合急診室嗎？奇美醫學中心在101年8月開立全人醫療科，以整合醫療(Holistic)的模式，照顧急診室住院待床病人同時將安寧療護帶入急診室，開啟了急診安寧療護照護模式。另外奇美醫學中心急診醫學部積極培育急診安寧人員，包括醫師及護理師，目前有兩位全人醫師取得安寧專科醫師，另有兩位急診醫師完成安寧醫師訓練，奇美醫學中心的急診住院醫師訓練亦需至安寧病房接受緩和醫學訓練一個月。目前已有兩位護理師完成安寧療護護理師訓練，並且成為安寧種子，於急診持續推廣安寧療護。 急診安寧服務的對象為急診病人，及早發現病人有安寧需求，除了原本的醫療外，醫療團隊也積極介入安寧療護，提供病人身體上的舒適醫療，讓病人家屬了解目前的醫療目標，達到安心目的。
中國阿膠2千噸疑慮 (驢皮/馬皮/騾皮 ?)
中國補品阿膠 市場4成偽原料 2016年01月27日【記者李源／綜合報導】在中國流傳已久的知名補血聖品「阿膠」，原是以驢皮熬製，但近日被曝出有近四成阿膠是由馬皮、騾皮、豬皮，甚至是工業用皮等替代原料製成。據中央社引述陸媒報導，有業界人士指出，以原料驢皮供應計算，阿膠年產量應只能生產3千噸，但目前市場銷量卻高達5千噸；意味市場有近四成的阿膠是由假冒原料製成。業界人士透露，一張驢皮要價2千至3千元（人民幣，以下同，約合新台幣1萬至1萬5千元），而一張馬皮、騾皮僅價值200元，豬皮和一些製作皮鞋、皮包所剩餘的坯料當然就更便宜。由於眾多不法業者製作假阿膠，也造成中國大陸市面上的產品價格相差甚遠，從每公斤400至4千元都有。若想買阿膠來補身的朋友，請眼睛睜大，不要貪便宜，以免買到仿冒品，因小失大。
新藥代號與股價聯結 (解盲股價)??!!
新藥代號有意思？ 法人解盲 浩鼎拚822元 2015年12月02日 04:10 記者杜蕙蓉／台北報導 銳不可當的生醫股，昨日持續引領風騷，法人以熱門新藥公司的新藥名稱解讀股價密碼，認為浩鼎（4174）乳癌新藥OBI-822的代號、中裕（4147）TMB-355的數字都暗藏玄機，本波2檔指標股攻勢，第一波火力將分別上看822元、355元。不過，由於昨日生醫股的成交量已有稍微降溫跡象，店頭生醫股在上櫃成交占比從過去的逾5成，昨日已降至40.14％，成交金額137.71億元，也較5日均量150.8億元偏低，生醫股是否還能天天狂飆，備受關注。已經讓股民看傻眼的生醫股，每天大演的爆熱行情，已引爆話題，生技何時會回檔？現在可以進場嗎？浩鼎、中裕要漲到何時？有趣的是，儘管市場不斷喊生醫股瘋了，浩鼎、中裕漲的太離譜，但昨天新科生技股王浩鼎盤中曾大漲9％，以741元再創新天價，而中裕則直奔漲停，以235元作收，不落人後的智擎也上漲7元，以278元收盤。另外，健亞、中裕、中天、智擎、晟德、東洋、南光、大江、盛弘交投也十分熱絡，擠身店頭股成交量前30名排行榜，而儘管法人已有調節浩鼎、健亞、中天、邦特現象，但東洋、晟德、智擎依舊受青睞。法人表示，目前市場盛傳以新藥股的新藥代號來「解盲」股價，浩鼎明年2月底前將公布數據的乳癌新藥OBI-822，股價有上看822元機會；中裕的TMB-355，表示股價可望來到355元，因此，智擎的胰臟癌新藥MM-398，也暗示股價有挑戰398元實力。另外，基亞的PI-88，就是數字不佳，去年因三期數據不如預期，股價最低時也摜破88元。如果照這種數字密碼解讀，那麼最吃香的是藥華藥用於治療真性紅血球增生症（PV）的P1101，數字是4位數！法人表示，生醫股挾著總統牌和尹衍樑將持續加碼投資的雙重利多效應，產業前景多頭趨勢不變，股價走勢也將是緩步上攻小回格局，為了蘊釀產業進入國際藥廠和投資機構的雷達區內，預期明年上半年以前，一定會有一、二檔股票有機會上看1千元，數據解盲成功或授權公司都會是標的。(工商時報)
順藥 新董監(林榮錦/鄭萬來/李忠良/謝德夫/蔡長海/李聖婉/陳慶(方方土))
順藥：公告本公司105年第一次股東臨時會全面改選董監事，董事變動已達1/3 鉅亨網／鉅亨網新聞中心-2016年01月26日第三十四條 第6款1.發生變動日期:105/01/262.舊任者姓名及簡歷:董事：晟德大藥廠股份有限公司 代表人：林榮錦/晟德大藥廠股份有限公司董事長董事：晟德大藥廠股份有限公司 代表人：李忠良/高林實業股份有限公司董事暨執行長董事：晟德大藥廠股份有限公司 代表人：陳俊宏/中天生物科技股份有限公司董事董事：安基生醫股份有限公司董事：鄭萬來/永彰機電股份有限公司董事長董事：順晟藥品有限公司 代表人：謝德夫/班友投資股份公司董事長董事：晟信投資顧問有限公司3.新任者姓名及簡歷:董事：晟德大藥廠股份有限公司 代表人：林榮錦/晟德大藥廠股份有限公司董事長董事：晟德大藥廠股份有限公司 代表人：鄭萬來/永彰機電股份有限公司董事長董事：晟德大藥廠股份有限公司 代表人：李忠良/高林實業股份有限公司董事暨執行長董事：順晟藥品有限公司 代表人：謝德夫/班友投資股份公司董事長董事：蔡長海/中國醫藥大學暨醫療體系董事長獨立董事：李聖婉/華聯生物科技股份有限公司總顧問；生揚管理顧問股份有限公司創辦人/總經理；生揚創業投資股份有限公司創辦人/總經理獨立董事：陳慶(方方土)/嘉信聯合會計師事務所合夥會計師4.異動情形（請輸入「辭職」、「解任」、「任期屆滿」或「新任」）:新任5.異動原因:全面改選6.新任董事選任時持股數:晟德大藥廠股份有限公司:26,742,000股順晟藥品有限公司：1,000股蔡長海：419,000股李聖婉：0股陳慶(方方土)：0股7.原任期（例xx/xx/xx至xx/xx/xx）:103/07/25~106/07/248.新任生效日期:105/01/269.同任期董事變動比率:6/710.其他應敘明事項:無
到宅醫師通過 漸凍人病友不凍!!
用愛「解凍」！醫師到宅服務送愛 【華人健康網 記者洪毓琪／台北報導】 2016年1月26日用愛「解凍」！對於罹患罕見疾病的漸凍人病友來說，不僅生活起居因肌肉萎縮而受限，生病就醫更是不便。所幸，在台北市立聯合醫院忠孝院區「居家醫療」照護「醫師到宅」服務的推行下，如今漸凍人病友即使不出門，也能得到妥善、健全的醫療照護，重新找回自我尊嚴。 台北市立聯合醫院忠孝院區葉啟昌副院長表示，生、老、病、死是萬物不變的定律，人類也是，不管你是貧，或是富，都早晚要面對它，經濟能力好的，就能自行處理；但經濟條件差的人，就有待社會各界，乃至政府來照料，做到「全人關懷，弱勢先行」的境界。自從台北市成立聯合醫院以來，過去各自為政，浪費醫療資源的現象已達到改善。且在資訊與採購方面的整合下，不僅有效提升市民就醫的便利性，更讓醫療品質有所進步。近年來，聯合醫院積極走入社區，落實社區型醫院的角色，推動家庭責任醫師制度，同時開展家戶關懷行動。化被動為主動！聯醫提供「醫師到宅」服務在104年度4月「醫療型家庭醫師責任制度」草案通過後，台北市立聯合醫院忠孝院區有感受在家醫制度的落實上，不能只靠深耕地方的診所基層醫師努力，社區醫院更是責無旁貸。有鑑於此，台北市立聯合醫院忠孝院區從104年度，便嘗試醫院功能行動化，化被動為主動，提供「醫師到宅」服務，直接將醫療服務直接送入有需求的民眾家中。
企業社會責任 驅動 農業創新 !
翻轉農業 104首創對企業募資 更新： 2016年01月27日【記者藍悅真／台北報導】以往募資都是以個人為主，104人力銀行與南澳自然田推出新的募資方式，首創對企業募資，104夢想搖籃營運長陳慧鈴表示，將農業耕種產物的需求與企業社會責任（CSR）結合，以創新的募資方式，達到更有效率的農業創新模式，目前已有仁寶和104等多家企業加入挺農，讓綠色行動從員工福利提升到企業認同。陳昌江說，「找農夫代耕」可以改善農藥造成的食安問題，透過契作代耕，事先約定好固定的利潤、以及指定的農作物，消除農民拚重量的動機，自然種出好食物，農夫只要提供專業服務，種出買家要的健康食物，農夫不用負擔產出後的銷售風險，立即變成守護台灣環境的一分子，消費者也能省掉中間的經銷通路，以合理的價格獲得安心好食材，當越多消費者加入代耕行列，越多的農夫可以安心種植。陳昌江自2010年起，即在宜蘭進行友善農耕「量產清淨食物，量產清淨土地」的夢想計畫。他觀察，2014年，台灣全體上市櫃公司營收達30.6兆元，全體獲利達1.86兆元，企業是很有能力解決台灣環境問題，尤其，企業社會責任CSR不再只是「捐一捐」、「秀一秀」，由企業認養稻田挺農夫，企業與農夫合作守護台灣。主計總處統計，2013年的非高齡專業農牧戶與2012年同期相比成長18.42%，大幅超越整體農牧戶年增幅0.12%，顯示現在有愈來愈多擁有跨領域專才的年輕人投身農業，以創新技術、行銷或商業模式，顛覆傳統農業。
盛弘 爭取敏盛委外洗腎業務 !!
長照/醫藥流通/專科經營齊發 盛弘今年本業拚續揚 MoneyDJ新聞 2016-01-22 10:12:58 記者 蕭燕翔 報導 醫藥流通挹注貢獻，盛弘(8403)去年第四季營收創下新高，法人估計，毛利率估將優於第三季，去年含業外貢獻下，每股稅後盈餘將有4元以上。而因盛弘是國內長照床數最具規模者之一，在新政府將長照政策列為施政重點項目下，備受關注，法人預期，公司今年營收將有5-7%成長，本業獲利挑戰六年高峰。盛弘是敏盛醫療集團的關聯企業，近年定位在醫療服務平台的整合廠商，目前營收比重仍以醫藥流通佔大宗，主要為醫療院所進行藥品與耗材的聯合採購。其餘還包括長照、健康管理、器材租賃服務等專科項目，這兩年開始跨足終端藥局經營，採用「盛康藥局」的品牌於雙北市及桃園區大舉拓點，去年底全台已有20家店。而盛弘去年第四季營收5.77億元，創下新高，該公司表示，除了代理國光疫苗(4142)進入季節旺季外，主要是藥局通路的貢獻成長。法人估計，上季毛利率可望較第三季增長，去年因有首季處分子公司十陸股權的業外挹注，全年每股稅後盈餘將有4元以上水準，是掛牌以來最佳。展望今年，盛弘的成長將來自藥局通路續拓點、專科經營及長照業務。其中在通路拓點上，法人估計，去年盛康藥局(註：對營收貢獻以非雙北市據點為主)對盛弘的營收貢獻約有一成，今年內部已喊出，年底據點將再增10家至30家，雖初期開店成本恐讓新點還難在短期獲利，不過公司因有集團的資源加持，在慢性處方箋市場具利基，且據點擴張也有利採購談判。在專科經營上，盛弘在兩岸都累積不錯基礎，其中透過醫管輸出，協助大陸旺旺醫院、北京嫣然醫院、明基醫院、山東青島婦幼醫院及內蒙/烏海的醫院升級，經營團隊也希望利用此基礎，爭取兩岸專科經營的商機。其中在台灣市場，盛弘新引進白內障無刀飛秒雷射的機台，用於敏盛醫院的眼科治療，9月引進手術單月僅開兩刀，目前已提高至14刀的損益兩平水準，今年目標能提高至20刀，並於台北覓點設立第二個眼科中心。盛弘也會爭取敏盛醫院過去委外的洗腎科業務經營機會，預計2017年發酵。另外，長照業務方面，盛弘去年持續將低度使用社區醫院的病床轉用照護床，推行「醫養結合」策略，去年底全台床數已達740床，今年底目標800床。公司也表示，考量文化、基礎建設與建置成本，該公司不考慮以併購方式拓增床數，但期許以醫養結合策略，帶動每年照護床數穩增。法人估計，盛弘今年營收可望穩增5-7%，因既有業務與轉投資如敏成(4431)等子公司，營運持續改善，本業獲利增幅有機會高於營收，營業利益將挑戰六年高峰。
東宇生技 董監提前全面改選
東宇生技：更正公告本公司105年第一次股東臨時會改選董事監察人 鉅亨網 2016/01/23 09:411.發生變動日期:105/01/202.舊任者姓名及簡歷:董事：吳靜翊、齊芯投資(股)公司代表人蕭家松、齊芯投資(股)公司代表人林鴻緯獨立董事：李國光監察人：關東麟3.新任者姓名及簡歷:董事：蕭家松、煥儷生物科技(股)公司代表人高志斌、煥儷生物科技(股)公司代表人林鴻緯獨立董事：李國光、薛乃維監察人：詠興投資有限公司代表人吳靜翊、詠興投資有限公司代表人林惠美、詠興投資有限公司代表人陳奮賢4.異動原因:提前全面改選5.新任董事選任時持股數:董事蕭家松：25,000,000股董事煥儷生物科技(股)公司代表人高志斌：250,000股董事煥儷生物科技(股)公司代表人林鴻緯：250,000股獨立董事李國光：0股獨立董事薛乃維：0股監察人詠興投資有限公司代表人吳靜翊：700,000股監察人詠興投資有限公司代表人林惠美：700,000股監察人詠興投資有限公司代表人陳奮賢：700,000股6.原任期（例xx/xx/xx至xx/xx/xx）:103/10/20~106/10/197.新任生效日期:105/01/208.同任期董事變動比率:不適用(提前全面改選)9.其他應敘明事項:無
克緹中國直銷成長(35億人民幣) 緊扣 佰研/麗豐 營運
陸直銷客戶動能仍存，佰研今年營運續創高可期 MoneyDJ新聞 2016-01-26 10:13:37 記者 蕭燕翔 報導 克緹訂單加持，保健品廠商佰研(3205)去年營運創下高峰，全年大賺一個資本額以上。市場分析，因大陸直銷產業近年維持約二成的自然成長，去年10月克緹獲批直銷區域可擴展至27個省、自治區及直轄區，在客戶會員及獲批銷售區域版圖持續擴增下，將帶動佰研今年營收仍有機會繳出高成長，獲利再創高峰可期。根據市場推估，佰妍目前的營收應有約八成來自保健品，多數來自近年在大陸直銷產業佈局有成的克緹。根據大陸媒體的報導顯示，中國目前核發執照的直銷商約49家，2014年統計的銷售數據以安利居首，克緹當年則以較前年成長超過兩倍至6.4億人民幣的速度，排名晉升至27名，而克緹去年公司派喊出的數據全年是要挑戰35億人民幣的銷售水準，排名可望大幅躍升，擠進前段班。不過，相較於大陸前五大直銷商年銷售額達100億人民幣的水準，克緹還有很大的成長空間；事實上，開放直銷業是大陸加入WTO的入世承諾，但為整頓亂象，官方近年也致力更明確定義直銷與金字塔式傳銷的差異，將合法直銷商列入商務部管轄範圍，克緹即是在2009年2月取得執照，但近三年在獲批銷售區域加速拓展下，營收才開始呈現跳躍式成長。 而佰研與F-麗豐(4137)去年起的業績都大舉受惠克緹的增長，前者是克緹保健品的代工廠商，後者則有兩款美容品的代工及商標授權收入進帳。根據市場的估計，佰研去年來自保健品的營收占比，應已有約八成水準，多數都來自克緹，也是營運創高的關鍵，今年能否持續走揚，克緹的業績動向仍甚為關鍵。業界評估，因中國大陸直銷產業近兩年可望都維持二成以上的自然成長，克緹去年兩度取得獲批銷售區域的新許可，最新的10月公告顯示，獲批區域已達27個省、自治區、直轄市，版圖幾乎已囊括大陸多數省分。在會員數與可銷售區域持續累積下，只要不出現預期外的變數，近幾年克緹仍將處於高速成長期，佰研也會同步受惠。業界認為，雖克緹連二年營收數倍跳升的成長，不會是長期的常態，但因相較龍頭與大陸整體直銷產業版圖，潛力仍大，未來幾年至少可以繳出優於產業平均的成長，會帶動佰研今年營運持續創高，獲利續登峰可期。而在獲利面，佰研去年獲利成長，除因該公司收款全為美元，第三季因台幣對美元貶幅較大，認列匯兌利益外，其餘多來自本業。也因該公司收款都來自美元，此波受人民幣走貶影響不大，今年盈餘成長仍賴本業動能。
長庚大學 拚青年創業 設 "北桃青創基地"
長庚大學辦理青創投資論壇 打造北桃青創基地(中央社訊息服務20160126 09:26:04)長庚大學將於1月29日辦理「2016生技醫療與資訊電子青年創業投資論壇與技術成果發表會」，會中除了分享長庚大學創新育成中心輔導廠商的特色發展及成果，更邀請來自產官學研的專家學者擔任與談人，深入探討青年創業投資於生技醫療與資訊電子領域中的相關議題，論壇對外開放，線上報名網址http://goo.gl/forms/YeBojomTYo，歡迎各界人士踴躍參與，座位有限，額滿為止。論壇在經濟部中小企業處、教育部及桃園市政府指導下，由長庚大學創新育成中心、長庚大學扎根計畫、桃園市政府青年事務局及安永聯合會計師事務所共同籌劃，並與財團法人資訊工業策進會、財團法人光電科技工業協進會、中華民國創業投資商業同業公會、證櫃檯買賣中心及台北市電腦商業同業公會共同主辦，產官學研代表齊聚一堂。長庚大學秉持創辦人王永慶先生「取之於社會，用之於社會」理念，主動為青年創新與創業思考，以其資訊電子技術資源，結合校內及庚醫療體系的健康醫療專業，與地方政府及公(協)會合作，盼能共同帶動區域產業發展，創造永續經濟價值動線及平台。此外，長庚大學今年也將在校園內投資新建第二創新育成中心(北桃青創基地)，協助推動地方樂活圈，帶動地方產業聚落及週邊產業「生技醫療與健康照護」、「資訊電子及光電」及「文創觀光」，推升社會經濟效益。透過推動青年創業與創新，長庚大學正往無圍牆大學目標邁進，不只是把學生實習場域擴大至周邊產業，也會把產業議題帶進校園，促使研發成果直接應用於產業發展，實現大學成為產業研發基地，形塑在地社會經濟特色，直接貢獻國家經濟發展。訊息來源：長庚大學
心悅: 院士概念股(朱敬一/吳妍華/吳成文) 主辦券商(富邦)認1300張(88.39元&168元)
心悅周五掛牌 法人捧 2016-01-26 05:01 經濟日報 記者黃文奇／台北報導 心悅生醫（6575）將在29日登錄興櫃，由於該公司旗下兩大精神病用藥產品獲得美國食品藥物管理局（FDA）認可為「突破性療法」（BTD），受到法人追捧。心悅不僅因BTD資格而聲名大噪，近期的第一屆薪酬委員會成員，包括三位中研院院士，朱敬一、吳妍華與吳成文，受到各界矚目。心悅目前資本額10.24億，法人表示，心悅有七大產品線，聚焦精神分裂正與早期失智症，長線來看競爭力看好。目前心悅主辦券商為富邦證券，協辦為日盛、台新、大展，主辦券商認購1,300張（含權），認購價格有兩個為88.39元與168元，均價約在120元上下，三家協辦券商認總計購近500張，價格為168元。據悉，全球精神病用藥市場約有150億美元，心悅目前在精神分裂領域，都有機會分食商機
白理查基因(白鴻賓) 573萬 委託中亞聯大(會員基因解碼)
學界唯一 亞大「中亞聯大食品安全檢測中心」把關食安 記者趙于婷／台北報導「中亞聯大食品安全檢測中心」最近通過衛生福利部食品藥物管理署 (TFDA) 認證，成為國家級認證實驗室，更是全國學界唯一可以檢驗動物性成分的國家級認證實驗室；中心主任徐國強表示，目前主要檢測服務項目包括食品動、植物成分攙偽、基因改造黃豆、玉米的篩檢、食品微生物、營養成分標示、食品中重金屬、黃麴毒素等。該中心建置符合國際級標準的實驗室規模，擁有最先進的儀器檢測設備、30多位教授級專業人員及碩士級檢驗人員，將利用基因檢測技術，提供業者、社會大眾食品安全檢測服務，徐國強主任指出，已與「白理查基因科技公司」簽訂產學合作計畫，已成為該中心第一家進駐檢驗室的育成廠商，目前白理查基因科技已提出573萬元的檢驗服務。亞大產學長林田富強調，白理查公司主要營運項目是醫學美容、人類疾病基因檢測，與食安中心簽訂為期2年、573萬元的產學合作計畫，將以最新技術為該公司會員鑑定基因密碼，評估個人基因性疾病的風險管理，並由亞大保健系營養師提供生活飲食諮詢。白理查公司董事長白鴻賓也表示，疾病基因檢測是該公司當前最重要的營運方向，期盼藉由產學界資源，共同為國人健康把關。
安克 肝癌/乳癌 超音波輔助系統 (CE Mark/ FDA將核准突破)
安克2創新產品 將通過歐盟、美國核准 2016年01月27日 04:10 李水蓮 今年生技產業前景一片看好，安克生醫預計，今年將有兩項創新產品，包括超音波組織病變檢測系統以及超音波血流分析系統，通過歐盟CE Mark以及美國FDA核准，將在肝癌、乳癌等癌症的早期診斷上，大有突破。安克生醫總經理陳正剛博士表示，安克已上市的甲狀腺超音波電腦輔助偵測診斷系統的升級已獲得歐盟CE Mark核准，目前正全力推廣至醫學中心、以及健檢中心，臺大醫院採購之外，長庚、成大、三總等多家醫學中心正在試用中，健檢中心則包括國內單日全身健檢人數最高的聯安健檢已正式啟用。同時安克有兩項創新產品，預計於今年通過歐盟CE Mark以及美國FDA核准上市許可，接著再向台灣TFDA申請。另一項則是超音波血流分析產品，可用於去除都卜勒超音波雜訊，分析動靜脈血流及血管分布情形，對於觀察早期腫瘤、器官病變以及血管硬化程度有極大助益，上市後可望應用於乳癌、腎臟等病變的早期診斷及預後治療。安克生醫並於1月25日至28日，在杜拜舉辦的「第41屆國際醫院設備藥品牙科設備暨復健保健展」，展出全球唯一獲上市許可的甲狀腺癌電腦輔助偵測診斷系統及發表上述兩項創新產品。不但可展現安克產品線源源不絕的創新力，更可直接與各個地區、國家潛在授權客戶及代理廠商接觸洽談。董事長李成家表示，安克生醫研發的產品走在世界前端，並且與歐盟、美國FDA的國際標準接軌，為台灣之光。在新政府大力帶動生技產業發展下，將成為新時代的明星產業。
(工商時報)
Subscribe to:
Posts (Atom)
Posts
